ACCC Rules for Research Peptides in Australia

What ACCC rules apply to research peptides in Australia?

The ACCC does not approve, register or certify research peptides. Its role is to enforce the Australian Consumer Law, which sits in Schedule 2 of the Competition and Consumer Act 2010. That law applies to any business trading in Australia, including suppliers of laboratory research compounds, and it prohibits conduct and statements that are misleading or deceptive. In practice, the ACCC rules most relevant to research peptides are not about the compounds themselves. They are about how a supplier describes, labels and advertises them.

This matters because research peptides are supplied strictly for laboratory and research use only. They are not approved for human or animal consumption, and they are not therapeutic goods. The central compliance question under the Australian Consumer Law is therefore simple to state and important to get right. Does the way a product is presented create a truthful, accurate impression, or could it mislead a reasonable person about what the product is and what it can lawfully be used for?

Who the ACCC is and what law it enforces

The Australian Competition and Consumer Commission is the national competition and consumer regulator. Among its functions, it enforces the Australian Consumer Law, a national framework that protects consumers and promotes fair trading. State and territory fair trading agencies share jurisdiction over the same law, so enforcement can come from more than one body.

The Australian Consumer Law is distinct from the rules administered by the Therapeutic Goods Administration. The two can apply at the same time, which is a point suppliers often miss.

• The ACCC focuses on fair trading and consumer protection: misleading conduct, false representations, pricing, availability claims and fake or incentivised reviews.
• The law it enforces applies to all businesses in trade or commerce, regardless of the product category.
• It operates independently of the TGA and of food standards bodies, though their remits can overlap on advertising.

Sections 18 and 29: the core prohibitions

Two provisions of the Australian Consumer Law do most of the work here. Section 18 prohibits conduct, in trade or commerce, that is misleading or deceptive or likely to mislead or deceive. It is broad and applies to almost any form of business communication, including websites, product pages, emails and social posts. A key feature is that intention does not matter. It is no defence to say a misleading impression was an honest mistake.

Section 29 is more specific. It prohibits false or misleading representations about goods and services, including representations about their standard, quality, grade, composition and the uses a product is fit for. For a research-compound supplier, that reaches claims about purity, testing, composition and the lawful purpose of the product.

The legal test is not whether a statement is literally true in isolation. It is whether a reasonable person, taking in the overall impression created, could be misled. A technically accurate sentence can still breach the law if the surrounding context, images or implications paint a misleading picture.

How this applies to health and efficacy claims

The most significant risk area for research compounds is the health claim. Under the Australian Consumer Law, a health claim includes any representation, whether stated outright or merely implied, that a product delivers a health, medical, performance or similar benefit. Because research peptides are supplied for laboratory research only and are not approved for human or animal use, presenting them as if they produce a personal benefit would create a false impression about what the product is for.

Implied claims carry the same weight as explicit ones. Suggestive language, benefit-led imagery, testimonials or before-and-after style content can all contribute to a misleading overall impression even where no single sentence makes a direct promise. The safest position for research-use-only content is to describe compounds factually and to avoid any suggestion of personal use or outcome.

• Avoid stating or implying the product treats, cures, heals, builds or improves anything.
• Avoid testimonials or case studies that imply a personal benefit to a reader.
• Avoid imagery or framing that suggests human or animal consumption.
• Describe what a compound is, not what it might do for a person.

ACCC and TGA: two regulators, overlapping ground

It helps to see where the two regulators sit. The TGA administers the Therapeutic Goods Act and the Therapeutic Goods Advertising Code, which govern how therapeutic goods may be advertised and supplied. The ACCC administers the Australian Consumer Law, which governs fair trading and misleading conduct by any business.

The overlap appears in advertising. If a product is promoted with therapeutic claims, that promotion can engage the TGA framework and, at the same time, the Australian Consumer Law if the claims are misleading. A single piece of marketing can therefore attract attention from more than one angle. For research-use-only suppliers, the cleanest way to stay clear of both is to make no therapeutic claims at all and to keep all content strictly educational and factual.

If you want a worked example of how category and legal status interact for a specific compound, our explainer on whether a common research peptide is legal in Australia walks through the general framing.

Is BPC-157 legal in Australia?

Why truthful research-use-only labelling matters

Research-use-only labelling signals that a compound is intended for laboratory and research contexts and is not approved for human or animal use. Under the Australian Consumer Law, that label only protects a supplier if the rest of the presentation is consistent with it. A research-use-only disclaimer sitting beneath benefit-led marketing or consumption-style imagery can itself become part of a misleading overall impression, because the stated label and the surrounding message contradict each other.

Truthful labelling therefore means more than adding a disclaimer. It means the product name, description, images, pricing and any supporting claims all align with the research-use-only reality. Accurate statements about composition, purity and testing should be supportable, because representations about standard and quality fall squarely within section 29.

• Keep the research-use-only status prominent and consistent across every touchpoint.
• Make sure purity, testing and composition statements are accurate and verifiable.
• Do not pair a research-use-only label with language or imagery implying personal use.
• Treat pricing, stock and availability claims as factually as product claims.

Practical compliance themes for suppliers and buyers

The ACCC has consistently signalled, across the health and wellness space generally, that it takes misleading health claims seriously and that implied claims and overall impression are central to how it assesses conduct. Without pointing to any specific matter, the recurring enforcement themes are instructive for anyone operating near this category.

For buyers, the same principles are a useful lens for assessing a supplier. A compliant, transparent supplier describes compounds factually, states research-use-only status clearly and backs quality claims with evidence rather than persuasion.

• Overall impression matters more than any single sentence.
• Implied and indirect claims are assessed, not just explicit promises.
• Representations about quality, testing and composition must be accurate and supportable.
• Fake, incentivised or misleading reviews are treated as misleading conduct.

How to spot a trustworthy supplier Research peptides buyer's guide

Key takeaways

The ACCC does not regulate the compounds themselves. It regulates how they are described and sold. For research peptides, that means the Australian Consumer Law applies to every product page, label and piece of marketing, and the governing test is whether a reasonable person could be misled by the overall impression.

Staying on the right side of the law is straightforward in principle. Keep content educational and factual, make no therapeutic or efficacy claims, state research-use-only status clearly and consistently, and ensure every representation about quality and composition is accurate. Where therapeutic claims would otherwise appear, the safest answer is to remove them entirely.